What is Eli Health?
Eli Health is a pioneering health-technology firm that has developed the Hormometer, an innovative system designed to provide instant, evidence-based insights into individual hormone levels. By offering rapid testing for key biomarkers such as cortisol, progesterone, and testosterone, the company empowers users to make informed, data-driven decisions regarding their personal health management. With a strong intellectual property portfolio comprising over 12 patents, Eli Health distinguishes itself through a commitment to high-accuracy, accessible diagnostic tools. The company operates at the intersection of consumer wellness and medical technology, targeting a growing demographic of health-conscious individuals who prioritize real-time physiological monitoring to optimize their daily well-being and long-term health outcomes.
How much funding has Eli Health raised?
Eli Health has raised a total of $6.3M across 3 funding rounds:
Angel/Seed
$1.5M
Angel/Seed
$3.7M
Private Equity
$1.1M
Angel/Seed (2021): $1.5M with participation from Techstars, Vectr Ventures Limited, 2048 Ventures, Real Ventures, Ramen Ventures, and Panache Ventures
Angel/Seed (2023): $3.7M led by Garage Capital, Cake Ventures, and Muse Capital
Private Equity (2025): $1.1M, investors not publicly disclosed
Key Investors in Eli Health
Real Ventures
Real Ventures serves mission-driven entrepreneurs and nurtures the communities in which they thrive, backing visionary founders building innovative tech companies that have large-scale positive impacts on society.
Garage Capital
Garage Capital is a venture capital firm dedicated to helping startups transition from early-stage development to growth, providing experienced-based advice to founders building category-defining businesses.
Cake Ventures
Cake Ventures is a seed-stage firm that invests in companies addressing demographic changes, with a specific focus on the evolving needs of internet users in areas such as health, wellness, and women's spending power.
What's next for Eli Health?
With the successful closure of this major enterprise-level funding, Eli Health is poised to enter a phase of aggressive market penetration and product diversification. The strategic roadmap likely includes the scaling of its manufacturing capabilities to meet rising consumer demand and the potential integration of its hormonal data sets into broader digital health ecosystems. By focusing on the intersection of demographic shifts and personalized medicine, the company is well-positioned to capitalize on the increasing demand for proactive health management solutions. Future initiatives will likely center on enhancing the user experience through advanced software integration and expanding the diagnostic range of the Hormometer platform to address a wider array of hormonal health indicators, thereby solidifying its competitive advantage in the health-tech landscape.
See full Eli Health company page
